G. Giannini

发表

A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer

A. Giuliani, L. Alexandrov, M. Bignami, 2017, EBioMedicine.

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

G. Giannini, F. Zunino, L. Musso, 2014, European journal of medicinal chemistry.

Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.

G. Giannini, F. Zunino, L. Musso, 2015, Bioorganic & medicinal chemistry letters.

Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.

G. Giannini, C. Fattorusso, C. Botta, 2011, Journal of medicinal chemistry.

NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.

R. Boldrini, G. Giannini, P. Natali, 2010, Cancer research.

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors

R. Boldrini, I. Screpanti, C. Dominici, 2014, Cell Death and Disease.

MiR‐128 up‐regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness

Giuseppe Giannini, C. Dominici, H. McDowell, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The role of peroxiredoxins in cancer

G. Giannini, C. Capalbo, A. Nicolussi, 2017, Molecular and clinical oncology.

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production

G. Giannini, A. Santoni, C. Capuano, 2017, Oncoimmunology.

Optimizing the identification of risk‐relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families

I. Screpanti, G. Giannini, L. Ottini, 2017, Cancer medicine.

N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.

G. Giannini, C. Pisano, L. Vesci, 2009, Bioorganic & medicinal chemistry letters.

Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup

I. Screpanti, G. Giannini, E. Miele, 2015, Biomarker Research.

Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.

G. Giannini, F. Zunino, L. Musso, 2012, European journal of medicinal chemistry.

HMGA Molecules in Neuroblastic Tumors

G. Giannini, A. Gulino, F. Cerignoli, 2004, Annals of the New York Academy of Sciences.

An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma.

Giuseppe Giannini, L. Di Marcotullio, I. Screpanti, 2008, Neoplasia.

Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14

I. Screpanti, G. Giannini, A. Gulino, 2014, Breast Cancer Research and Treatment.

Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives.

G. Giannini, F. Arcamone, A. Garbesi, 1997, Nucleic acids research.

Azetidinones as Zinc‐Binding Groups to Design Selective HDAC8 Inhibitors

Walter Cabri, Sergio Penco, Grazia Gallo, 2009, ChemMedChem.

2-Azetidinones: synthesis of new bis(indolyl)butyl-β-lactams

G. Giannini, W. Cabri, A. Quintavalla, 2010 .

Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity.

G. Giannini, F. Zunino, S. Dallavalle, 2005, Journal of medicinal chemistry.

Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.

G. Giannini, C. Pisano, L. Vesci, 2009, Bioorganic & medicinal chemistry letters.

2-Aminopurine Unravels a Role for pRB in the Regulation of Gene Expression by Transforming Growth Factor β*

L. Di Marcotullio, I. Screpanti, G. Giannini, 1997, The Journal of Biological Chemistry.

Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer.

I. Screpanti, G. Giannini, A. Gulino, 2015, Clinical biochemistry.

The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1

I. Screpanti, G. Giannini, M. Levrero, 2013, Molecular carcinogenesis.

Absolute Configuration of the Fungal Metabolite Spirolaxine

G. Giannini, S. V. Meille, L. Malpezzi, 2005 .

An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

P. Paci, G. Giannini, V. Licursi, 2022, Biology direct.

Coexistence of three EGFR mutations in an NSCLC patient: A brief report

G. Giannini, C. Nicolazzo, A. Gradilone, 2018, The International journal of biological markers.

Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination

I. Screpanti, A. Greco, G. Giannini, 2006, Nature Cell Biology.

Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.

G. Giannini, R. Baruchello, C. Pisano, 2011, Journal of medicinal chemistry.

PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.

G. Giannini, G. Mincione, F. Nardi, 2014, International journal of oncology.

PRDX 1 and PRDX 6 are repressed in papillary thyroid carcinomas via BRAF V 600 E-dependent and-independent mechanisms

G. Giannini, M. Marcantonio, G. Mincione, 2013 .

Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status

I. Screpanti, G. Giannini, L. Frati, 2000, British Journal of Cancer.

Novel N-acetyl-Glycol-split heparin biotin-conjugates endowed with anti-heparanase activity.

G. Giannini, G. Roscilli, I. Vlodavsky, 2019, European journal of medicinal chemistry.

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Annette Lee, W. Chung, R. Nussbaum, 2018, Human mutation.

KCTD15 inhibits the Hedgehog pathway in Medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2

L. Di Marcotullio, D. Guardavaccaro, G. Giannini, 2019, Oncogenesis.

The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases

F. Sera, D. Palli, G. Giannini, 2010, European Journal of Human Genetics.

Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.

G. Giannini, S. Hanessian, C. Pisano, 2007, Bioorganic & medicinal chemistry letters.

retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines.

I. Screpanti, C. Thiele, G. Giannini, 2002, Cancer research.

Biological and molecular properties of a new A v B 3 / A v B 5 integrin antagonist

D. Ribatti, B. Nico, A. Ciucci, 2005 .

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation† †Electronic supplementary information (ESI) available: Experimental procedures, biological activity data, NMR spectra for characterisation. See DOI: 10.1039/c7sc05266a

G. Giannini, A. Anastasi, R. De Santis, 2018, Chemical science.

Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.

G. Giannini, F. Zunino, L. Musso, 2010, Bioorganic & medicinal chemistry.

Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy

B. Bonanni, P. Radice, P. Peterlongo, 2019, International journal of cancer.

A Simpliﬁed Genomic Proﬁling Approach Predicts Outcome in Metastatic Colorectal Cancer

M. Filetti, D. Bellavia, P. Paci, 2019 .

Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.

G. Giannini, F. Zunino, L. Musso, 2016, European journal of medicinal chemistry.

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk

B. Bonanni, P. Radice, P. Peterlongo, 2019, Endocrine Connections.

Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.

G. Giannini, S. Rivara, F. Milazzo, 2016, Future medicinal chemistry.

Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy

P. Radice, P. Peterlongo, S. Manoukian, 2014, Breast Cancer Research and Treatment.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.

G. Giannini, L. Musso, S. Dallavalle, 2010, Bioorganic & medicinal chemistry.

Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues.

G. Batist, G. Giannini, M. Alaoui-Jamali, 2003, Molecular cancer therapeutics.

PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress

I. Screpanti, D. Bellavia, A. Greco, 2013, Cell Death and Differentiation.

Gene panel mutation screening for a better molecular stratification of colorectal cancer patients

D. Raimondo, G. Giannini, G. Troncone, 2018 .

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer

G. Giannini, E. Cortesi, C. Nicolazzo, 2019, Cancers.

Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival.

I. Screpanti, D. Bellavia, G. Giannini, 1996, Journal of immunology.

5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance

M. V. Giuli, I. Screpanti, D. Bellavia, 2022, Frontiers in Oncology.

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study

G. Giannini, F. Di Nicolantonio, E. Cortesi, 2022, Cancers.

True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.

G. Giannini, F. Di Nicolantonio, I. Bottillo, 2021, Cancer letters.

Male breast cancer in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, F. Couch, 2018 .

Peer Review #2 of "Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer (v0.1)"

G. Giannini, C. Capalbo, M. Petroni, 2019 .

Synthesis of Bromoundecyl Resorc[4]arenes and Applications of the Cone Stereoisomer as Selector for Liquid Chromatography.

C. Massera, A. Ciogli, G. Giannini, 2018, The Journal of organic chemistry.

PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma

I. Screpanti, G. Giannini, A. Gulino, 2017, Oncogene.

Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.

M. Filetti, G. Giannini, P. Marchetti, 2018, Molecular and clinical oncology.

Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome.

L. Mele, L. Pagano, G. Leone, 2003, DNA repair.

4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.

G. Giannini, R. Baruchello, L. Vesci, 2014, European journal of medicinal chemistry.

Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.

G. Giannini, F. Zunino, L. Musso, 2012, European journal of medicinal chemistry.

Whole‐exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene

B. Bonanni, P. Radice, P. Peterlongo, 2017, Cancer.

Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?

I. Screpanti, G. Giannini, E. Ricevuto, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel combretastatin analogues endowed with antitumor activity.

G. Giannini, M. Rizzi, R. Baruchello, 2006, Journal of medicinal chemistry.

Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides.

D. Potenza, L. Belvisi, A. Bernardi, 2001, Organic letters.

Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.

G. Giannini, L. Musso, S. Dallavalle, 2018, Bioorganic & medicinal chemistry letters.

Molecular mechanism of HMGA1 deregulation in human neuroblastoma.

G. Giannini, A. Gulino, F. Cerignoli, 2005, Cancer letters.

High mobility group A1 is a molecular target for MYCN in human neuroblastoma.

I. Screpanti, C. Dominici, G. Giannini, 2005, Cancer research.

Structural Characterization of Human Heat Shock Protein 90 N-Terminal Domain and Its Variants K112R and K112A in Complex with a Potent 1,2,3-Triazole-Based Inhibitor

G. Giannini, S. Mangani, E. Cini, 2022, International journal of molecular sciences.

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors

G. Giannini, A. Bartolazzi, G. Canettieri, 2021, Oncogene.

The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress

L. Di Marcotullio, I. Screpanti, G. Giannini, 2015, Cell Death and Differentiation.

Thrombospondin-1 is a mediator of the neurotypic differentiation induced by EGF in thymic epithelial cells.

L. Di Marcotullio, I. Screpanti, G. Giannini, 1999, Experimental cell research.

Vorinostat-like molecules as structural, stereochemical, and pharmacological tools.

G. Giannini, A. Larsson, S. Hanessian, 2010, ACS medicinal chemistry letters.

NF- κ B, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells

R. Boldrini, G. Giannini, P. Natali, 2010 .

The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers

P. Radice, P. Peterlongo, S. Manoukian, 2011, Breast Cancer Research and Treatment.

Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition.

G. Giannini, E. Ermini, F. Migliorini, 2021, Chemical communications.

Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.

G. Giannini, S. Hanessian, L. Auzzas, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.

G. Giannini, F. Manetti, C. Pisano, 2014, Journal of medicinal chemistry.

Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.

G. Giannini, R. De Santis, F. Manetti, 2018, European journal of medicinal chemistry.

New classes of potent heparanase inhibitors from ligand-based virtual screening

G. Giannini, M. Mor, F. F. Ferrara, 2020, Journal of enzyme inhibition and medicinal chemistry.

MUC Gene Abnormalities in Sporadic and Hereditary Mucinous Colon Cancers with Microsatellite Instability

A. Viel, M. Fornasarig, G. Giannini, 2005, Disease markers.

Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors.

L. Tei, G. Giannini, C. Albertoni, 2019, Bioorganic & medicinal chemistry.

A MYCN-MRN complex axis controls replication stress for the safe expansion of neuroprogenitor cells

G. Giannini, M. Petroni, 2016, Molecular & cellular oncology.

Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors.

G. Giannini, R. Baruchello, T. Bernardi, 2017, Bioorganic & medicinal chemistry letters.

Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting*

G. Giannini, C. Pisano, G. Torri, 2005, Journal of Biological Chemistry.

Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.

G. Giannini, A. Naggi, A. Alekseeva, 2017, Carbohydrate polymers.

Genome-wide association study identifies a novel variant in RAD51B associated with male breast cancer risk

A. Ashworth, S. Novaković, M. Zvelebil, 2012, Nature Genetics.

Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell growth and inhibit apoptosis in neuronal and HL-60 cells.

G. Giannini, N. Gebbia, R. Baruchello, 2005, Journal of medicinal chemistry.

7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.

G. Giannini, F. Zunino, P. Perego, 2014, Bioorganic & medicinal chemistry.

Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.

G. Giannini, S. Dallavalle, L. Vesci, 2014, Bioorganic & medicinal chemistry letters.

Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.

G. Giannini, M. Rizzi, R. Baruchello, 2008, Journal of medicinal chemistry.

Cyclic RGD peptides containing azabicycloalkane reverse-turn mimics

D. Potenza, L. Belvisi, G. Giannini, 2002 .

Synthesis and DNA-cleaving activity of lactenediynes conjugated with DNA-complexing moieties.

G. Giannini, L. Musso, A. Basso, 2008, Bioorganic & medicinal chemistry.

Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.

G. Giannini, A. Larsson, S. Hanessian, 2010, Journal of medicinal chemistry.

Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines.

G. Giannini, N. Gebbia, R. Baruchello, 2005, Journal of medicinal chemistry.

Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.

G. Giannini, C. Pisano, Laura Muzi, 2006, Journal of medicinal chemistry.

Microbial Transformation of Spirolaxine, a Bioactive Undecaketide Fungal Metabolite from the Basidiomycete Sporotrichum laxum

G. Giannini, G. Nasini, G. Fronza, 2007, Chemistry & biodiversity.

Synthesis of 5,6‐dihydro‐4H‐benzo[d]isoxazol‐7‐one and 5,6‐dihydro‐4H‐isoxazolo[5,4‐c]pyridin‐7‐one Derivatives as Potential Hsp90 Inhibitors

G. Giannini, L. Musso, S. Dallavalle, 2015, Chemical biology & drug design.

Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.

G. Giannini, Gianfranco Battistuzzi, D. Vignola, 2015, Bioorganic & medicinal chemistry letters.

Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids.

D. Potenza, L. Belvisi, A. Bernardi, 2006, Bioorganic & medicinal chemistry.

E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.

G. Giannini, F. Zunino, C. Pisano, 2008, Bioorganic & medicinal chemistry letters.

Camptothecin and Analogs

G. Giannini, 2014 .

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, F. Couch, 2017, Journal of the National Cancer Institute.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

R. Nussbaum, D. Steinemann, F. Couch, 2016, Breast Cancer Research.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2014, Breast Cancer Research.

Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy

P. Radice, P. Peterlongo, S. Manoukian, 2012, Breast Cancer Research and Treatment.

Ruthenium-catalyzed synthesis of 5-amino-1,2,3-triazole-4-carboxylates for triazole-based scaffolds: beyond the dimroth rearrangement.

G. Giannini, M. Taddei, A. Tafi, 2015, The Journal of organic chemistry.

A convenient synthesis of unsymmetrically substituted terphenyls of biologically active stilbenes via a double Suzuki cross-coupling protocol

G. Giannini, R. Baruchello, M. Roberti, 2003 .

The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.

G. Giannini, E. Ballana, R. Badia, 2015, Antiviral research.

Synthesis and biological activity of fluorinated combretastatin analogues.

G. Giannini, C. Pisano, W. Cabri, 2008, Journal of medicinal chemistry.

ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP

L. Di Marcotullio, D. Bellavia, G. Melino, 2019, Nature Communications.

The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering

A. Angelucci, G. Giannini, A. Gulino, 1998, Cell Death and Differentiation.

HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.

L. Di Marcotullio, I. Screpanti, M. Crescenzi, 1999, Cancer research.

Responsiveness Cell Lines and Tumors and Affect Retinoic Acid Genes Are Expressed in Neuroblastoma HMGI-C and HMGI ( Y ) Updated

I. Screpanti, M. Crescenzi, G. Giannini, 1999 .

BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.

G. Giannini, E. Ricevuto, A. Gulino, 2006, Critical reviews in oncology/hematology.

Synthesis and cytotoxic activity of polyamine analogues of camptothecin.

G. Giannini, F. Zunino, L. Musso, 2006, Journal of medicinal chemistry.

Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.

I. Screpanti, G. Giannini, L. Frati, 2008, Neoplasia.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families

I. Screpanti, G. Giannini, E. Ricevuto, 2006, Breast Cancer Research and Treatment.

Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation

A. Fatica, L. Di Marcotullio, G. Giannini, 2020, Cell Death & Disease.

Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer

P. Paci, D. Raimondo, G. Giannini, 2020, Frontiers in Oncology.

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma

G. Giannini, A. Gulino, V. Veschi, 2012, Front. Oncol..

Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology

G. Giannini, L. Ottini, G. d’Amati, 2023, Frontiers in Oncology.

Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain.

I. Screpanti, G. Giannini, E. Ricevuto, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

J. Khan, E. Appella, Ying Hu, 2017, Cancer cell.

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases

D. Palli, G. Giannini, S. Tommasi, 2008, Breast Cancer Research and Treatment.

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

G. Giannini, B. Cardinali, G. Ruberti, 2015, PloS one.

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

A. Zullo, G. Giannini, P. Marchetti, 2013, OncoTargets and therapy.

MRE11 expression is impaired in gastric cancer with microsatellite instability.

D. Palli, G. Giannini, M. Paglierani, 2004, Carcinogenesis.

Human MRE11 is inactivated in mismatch repair‐deficient cancers

Alessandra Viel, Fabio Cerignoli, Marco Crescenzi, 2002, EMBO reports.

BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy

F. Sera, S. Bianchi, D. Palli, 2009, Breast Cancer Research and Treatment.

A novel BRCA2 splice variant identified in a young woman

G. Giannini, L. Ottini, C. Capalbo, 2020, Molecular genetics & genomic medicine.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer

G. Sanguineti, G. Giannini, L. Strigari, 2016, Journal of experimental & clinical cancer research : CR.

Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module.

L. Di Marcotullio, G. Giannini, L. Battistini, 2020, Cell reports.

Quinolines and Oxazino-quinoline Derivatives as Small Molecule GLI1 Inhibitors Identified by Virtual Screening.

G. Giannini, Snigdha Singh, P. Governa, 2022, ACS medicinal chemistry letters.

Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.

Fabrizio Manetti, Barbara Stecca, Roberta Santini, 2020, ACS medicinal chemistry letters.

A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer

M. Filetti, D. Bellavia, P. Paci, 2019, Cancers.

EGF‐ and cell‐cycle–regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer

L. Di Marcotullio, I. Screpanti, G. Giannini, 2003, Molecular carcinogenesis.

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer

G. Giannini, E. Cortesi, C. Nicolazzo, 2019, Front. Oncol..

A gene dosage‐dependent effect unveils NBS1 as both a haploinsufficient tumour suppressor and an essential gene for SHH‐medulloblastoma

L. Di Marcotullio, P. Paci, Zhao-Qi Wang, 2022, Neuropathology and applied neurobiology.

Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.

G. Giannini, C. Fattorusso, W. Cabri, 2012, Future medicinal chemistry.

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer

C. Catalano, G. Giannini, P. Marchetti, 2014, Cancer biology & therapy.

Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance

S. Fox, S. Bianchi, D. Palli, 2021, Cancers.

FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC

D. Cappellen, G. Giannini, A. Lespagnol, 2023, Pathology & Oncology Research.

Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data

G. Giannini, L. Ottini, C. Capalbo, 2019, PeerJ.

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer

G. Giannini, L. Ottini, C. Capalbo, 2019, PeerJ.

Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2015 .

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software

I. Screpanti, G. Giannini, E. Ricevuto, 2006, European Journal of Human Genetics.

MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response

I. Screpanti, C. Dominici, H. McDowell, 2010, Molecular Cancer Research.

Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells

I. Screpanti, C. Dominici, G. Giannini, 2012, PloS one.

ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.

G. Giannini, M. Mor, C. Pisano, 2014, Journal of medicinal chemistry.

Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy.

P. Radice, P. Peterlongo, S. Manoukian, 2015, European journal of cancer.

PIK3CA somatic mutation in sinonasal teratocarcinosarcoma.

G. Giannini, F. Giangaspero, A. Corsi, 2020, Auris, nasus, larynx.

Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor

G. Giannini, E. Gaudio, R. De Santis, 2014, Oncotarget.

Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy

P. Radice, P. Peterlongo, S. Manoukian, 2013, Breast Cancer Research and Treatment.

Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist

D. Ribatti, B. Nico, A. Ciucci, 2005, Molecular Cancer Therapeutics.

The coactivator CRTC1 promotes cell proliferation and transformation via AP-1

I. Screpanti, G. Giannini, A. Gulino, 2009, Proceedings of the National Academy of Sciences.

Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability

I. Screpanti, A. Viel, G. Giannini, 2004, Oncogene.

Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments

G. Giannini, I. Bottillo, P. Grammatico, 2021, Diagnostics.

The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.

A. Porcellini, D. Mercola, G. Giannini, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activation of Three Distinct RXR/RAR Heterodimers Induces Growth Arrest and Differentiation of Neuroblastoma Cells*

C. Thiele, G. Giannini, M. Dawson, 1997, The Journal of Biological Chemistry.

The Early Growth Response Gene EGR-1 Behaves as a Suppressor Gene That Is Down-Regulated Independent of ARF / Mdm 2 but not p 53 Alterations in Fresh Human Gliomas 1

A. Porcellini, D. Mercola, G. Giannini, 2001 .

The Control of Heparanase Through the Use of Small Molecules.

Silvia Rivara, Giuseppe Giannini, Gianfranco Battistuzzi, 2020, Advances in experimental medicine and biology.

Roneparstat and Heparanase Inhibition: A New Tool for Cancer Treatment

G. Giannini, D. Ralph, P. Barbieri, 2017 .

Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2014, Cancer Epidemiology, Biomarkers & Prevention.

PALB2 mutations in male breast cancer: a population-based study in Central Italy

S. Bianchi, D. Palli, G. Giannini, 2010, Breast Cancer Research and Treatment.

Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy

G. Giannini, A. Angeloni, A. Montali, 2018, Scientific Reports.

New mutations and protein variants of NBS1 are identified in cancer cell lines

G. Giannini, E. Ricevuto, P. Marchetti, 2003, Genes, chromosomes & cancer.

MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors

L. Di Marcotullio, G. Giannini, S. Soddu, 2018, Cell Death & Disease.

New retinoid derivatives as back-ups of Adarotene.

G. Giannini, S. Dallavalle, F. Bucci, 2011, Bioorganic & medicinal chemistry.

Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.

Benito Casu, Marco Presta, Sergio Penco, 2002, Biochemistry.

A novel atypical retinoid endowed with proapoptotic and antitumor activity.

G. Giannini, F. Zunino, C. Gaetano, 2003, Journal of medicinal chemistry.

SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors

G. Giannini, A. Tessitore, G. Canettieri, 2019, Scientific Reports.

Combined inhibition of polyamine metabolism and eIF5A hypusination suppresses colorectal cancer growth through a converging effect on MYC translation.

A. Fatica, L. Di Marcotullio, G. Giannini, 2023, Cancer letters.

Identification and Characterization of BRCA 1 and BRCA 2 Founder Mutations

S. Iacobelli, G. Giannini, F. Baudi, 2012 .

Gli2 Acetylation at Lysine 757 Regulates Hedgehog-Dependent Transcriptional Output by Preventing Its Promoter Occupancy

L. Di Marcotullio, I. Screpanti, G. Giannini, 2013, PloS one.

HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report

G. Giannini, L. Frati, L. Manganaro, 2011, International journal of molecular sciences.

Chrysanthones, a new source of fungal metabolites with potential antitumor and antiangiogenesis properties.

G. Giannini, G. Candiani, G. Nasini, 2003, Fitoterapia.

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation

M. King, W. Foulkes, C. Lázaro, 2011, Breast Cancer Research and Treatment.

Undersulfated and glycol-split heparins endowed with antiangiogenic activity.

D. Ribatti, G. Giannini, M. Rusnati, 2004, Journal of medicinal chemistry.

Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families

I. Screpanti, G. Giannini, E. Ricevuto, 2007, Breast Cancer Research and Treatment.

The novel atypical retinoid ST5589 down‐regulates Aurora Kinase A and has anti‐tumour activity in lymphoma pre‐clinical models

L. Cascione, G. Giannini, A. Stathis, 2015, British journal of haematology.

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer

G. Giannini, F. Di Nicolantonio, D. Santini, 2023, Frontiers in Oncology.

Kras/ADAM17-dependent Jag1-ICD reverse signalling sustains colorectal cancer progression and chemoresistance.

L. Di Marcotullio, I. Screpanti, D. Bellavia, 2019, Cancer research.

BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.

A Gulino, I. Screpanti, G. Giannini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.

G. Giannini, L. Vesci, W. Cabri, 2014, Bioorganic & medicinal chemistry letters.

Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity.

G. Giannini, M. Mor, G. Cassinelli, 2018, Journal of medicinal chemistry.

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.

G. Giannini, N. Zaffaroni, F. Zunino, 2015, Biochemical pharmacology.

Characterization of therapeutic protein AvidinOX by an integrated analytical approach

L. Tei, G. Giannini, R. De Santis, 2017, Analytical and Bioanalytical Chemistry.

Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity.

G. Giannini, M. Mor, G. Cassinelli, 2018, Journal of medicinal chemistry.

Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup

I. Screpanti, G. Giannini, E. Miele, 2015, Biomarker Research.

Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.

B. Bonanni, P. Radice, P. Peterlongo, 2023, European journal of cancer.

ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1

G. Giannini, A. Anastasi, R. De Santis, 2020, Frontiers in Oncology.

Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase

G. Giannini, M. Mor, G. Roscilli, 2016, Glycobiology.

The Multiple Faces of the MRN Complex: Roles in Medulloblastoma and Beyond

G. Giannini, M. Petroni, Stefano Di Giulio, 2023, Cancers.

MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors

L. Di Marcotullio, G. Giannini, S. Soddu, 2018, Cell Death & Disease.

EGF regulates a complex pattern of gene expression and represses smooth muscle differentiation during the neurotypic conversion of the neural-crest-derived TC-1S cell line.

L. Di Marcotullio, I. Screpanti, G. Giannini, 2001, Experimental cell research.

Metal-organic frameworks (MOFs) as biomolecules drug delivery systems for anticancer purposes.

G. Giannini, D. Secci, Paolo Guglielmi, 2022, European journal of medicinal chemistry.

Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth.

E. Dreassi, G. Giannini, A. Lapucci, 2023, Pharmacological research.

A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy

S. Pileri, E. Ghia, E. Sabattini, 2006, Leukemia & lymphoma.

A multidisciplinary approach for the differential diagnosis between multiple primary lung adenocarcinomas and intrapulmonary metastases.

F. Venuta, M. Anile, G. Giannini, 2021, Pathology, research and practice.

Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites.

G. Giannini, Gianfranco Battistuzzi, 2015, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids.

G. Giannini, F. Zunino, S. Dallavalle, 2007, Bioorganic & medicinal chemistry.

Camptothecins in tumor homing via an RGD sequence mimetic.

G. Giannini, C. Pisano, L. Vesci, 2012, Bioorganic & medicinal chemistry letters.

Synthesis of ST7612AA1, a Novel Oral HDAC Inhibitor, via Radical  Thioacetic Acid Addition

G. Giannini, Gianfranco Battistuzzi, 2016, Current bioactive compounds.

Corrigendum to “N-Hydroxy-(4-oxime)-cinnamide: A versatile scaffold for the synthesis of novel histone deacetilase (HDAC) inhibitors” [Bioorg. Med. Chem. Lett. 19 (2009) 2346]

G. Giannini, C. Pisano, L. Vesci, 2009 .

N-formimidoyl analogues of distamycin

M. Dentini, G. Giannini, E. Monteagudo, 1996 .

Direct Correlation Between Double K-RAS Mutation and Mucinous Carcinoma. A Case Report

G. Giannini, V. Petrozza, Daniela Bastianelli, 2015, Applied immunohistochemistry & molecular morphology (Print).